Highly frequent anti‐idiotype antibody in cynomolgus monkeys developed against mouse‐derived regions of anti‐Fas antibody humanized by complementarity determining region grafting
Authors:
Open Access
- 28 August 2009
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 158 (2) , 548-557
Abstract
Background and purpose: We investigated the immunogenicity of a humanized anti‐human Fas monoclonal antibody, R‐125224, in cynomolgus monkeys to estimate its efficacy, as well as its toxicity in clinical situations.Experimental approach: R‐125224 was intravenously administered to cynomolgus monkeys at single doses of 0.4, 1.2, 6 and 30 mg·kg−1, and the plasma concentrations of R‐125224 and anti‐R‐125224 antibody (ARA) were measured. We conducted a competitive enzyme‐linked immunosorbent assay to determine which part of R‐125224 was recognized by ARA. We also examined the retention of radioactivity in mononuclear cells and granulocytes after the injection of [125I]‐R‐125224 to a collagen‐induced arthritis monkey model.Key results: After i.v. administration of R‐125224, the elimination of the plasma R‐125224 concentrations was accelerated at around 10 days post‐dose, and 10 of 12 monkeys were ARA positive. From an epitope analysis of ARA, the ARA produced in monkeys recognized the mouse‐derived regions located in complementarity determining regions, but could not recognize the human IgG. After the injection of [125I]‐R‐125224 to a collagen‐induced arthritis monkey model, a significantly longer retention of the radioactivity in mononuclear cells compared to granulocytes was observed.Conclusions and implications: In monkeys, the development of antibodies against R‐125224 is rapid and highly frequent. Our hypothesis is that this highly frequent development of ARA might be due to the binding of R‐125224 to immune cells, and its circulation in monkey blood might contribute to an increase in its chances of being recognized as an immunogen.Keywords
This publication has 30 references indexed in Scilit:
- Tissue distribution of humanized anti-human Fas monoclonal antibody (R-125224) based on fas antigen–antibody reaction in collagen-induced arthritis monkeysLife Sciences, 2007
- Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti‐CD40 antibody (SGN‐40) in rodents and non‐human primatesBritish Journal of Pharmacology, 2006
- A humanized anti-human Fas antibody, R-125224, induces apoptosis in type I activated lymphocytes but not in type II cellsInternational Immunology, 2005
- TISSUE DISTRIBUTION AND RECEPTOR-MEDIATED CLEARANCE OF ANTI-CD11A ANTIBODY IN MICEDrug Metabolism and Disposition, 2005
- Suppression of osteoclastogenesis in rheumatoid arthritis by induction of apoptosis in activated CD4+ T cellsArthritis & Rheumatism, 2003
- Therapeutic Effect of Novel Anti-Human Fas Antibody HFE7A on Graft-versus-Host Disease ModelClinical Immunology, 2001
- Stat1 as a Component of Tumor Necrosis Factor Alpha Receptor 1-TRADD Signaling Complex To Inhibit NF-κB ActivationMolecular and Cellular Biology, 2000
- Sequential Analysis of Apoptosis Induction in Peripheral Blood Mononuclear Cells and Lymph Nodes in the Early Phase of Pathogenic and Nonpathogenic SIVmac InfectionAIDS Research and Human Retroviruses, 1999
- TNF-α and IFN-γ render microglia sensitive to Fas ligand-induced apoptosis by induction of Fas expression and down-regulation of Bcl-2 and Bcl-xLEuropean Journal of Immunology, 1998
- The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosisCell, 1991